Immunai

Immunai is a biotech company that applies artificial intelligence to decode the human immune system, with the aim of accelerating drug discovery. The company's work sits at the intersection of AI, computational biology, machine learning, and single-cell multiomics. Its team brings together immunologists, engineers, drug developers, and computer scientists, with roots in research institutions including MIT and Harvard.

The company's core asset is AMICA, described as the world's largest immune-focused single-cell database, containing harmonized data from thousands of samples. This database underpins an end-to-end platform designed to support pharmaceutical and research partners across the drug development pipeline, from target discovery and preclinical evaluation through to clinical trial optimization.

Immunai's work spans several therapeutic areas, including immuno-oncology and autoimmune diseases. The company's stated goal is to bring breakthrough medicines to patients faster by improving decision-making at each stage of drug development.